Endothelin as a therapeutic target in the treatment of cardiovascular disease

Heart Dis. 2001 May-Jun;3(3):176-88. doi: 10.1097/00132580-200105000-00008.

Abstract

Endothelins, a family of peptides derived from the vascular endothelium and smooth muscle cells possess vasoconstrictor and mitogenic properties. By acting predominantly in a paracrine fashion, these peptides activate specific receptors and have protean effects in normal and diseased organ systems. The wide distribution of these receptors in various tissues mediate the multiplicity of physiologic actions attributed to endothelins. Much of our understanding about endothelins has come from the development of an array of receptor-specific and mixed receptor antagonists. Based on the promising results from animal studies, active research and drug development programs are under way to investigate the clinical potential of endothelin antagonism for treatment of cardiovascular disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism*
  • Cardiovascular Diseases / physiopathology
  • Endothelin Receptor Antagonists
  • Endothelins / antagonists & inhibitors
  • Endothelins / metabolism*
  • Endothelins / therapeutic use*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology
  • Humans
  • Receptors, Endothelin / therapeutic use
  • Treatment Outcome
  • Vasoconstrictor Agents / antagonists & inhibitors
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Endothelin Receptor Antagonists
  • Endothelins
  • Receptors, Endothelin
  • Vasoconstrictor Agents